Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SmithKline Beecham's Nicorette/Nicoderm CQ generate $345 mil. in sales in 1996.

This article was originally published in The Tan Sheet

Executive Summary

SMITHKLINE NICORETTE/NICODERM CQ SALES TOTAL $345 MIL. IN 1996, pacing SmithKline Beecham OTC product sales to a 20% increase to [pound]1.4 bil., or $2.37 bil. ([pound]1=$1.70), SB reported Feb. 18. Nicorette smoking cessation gum was launched in the first quarter of 1996, Nicoderm CQ transdermal patches in the third quarter. Together, the products captured 87% of the U.S. market for smoking cessation products, the company said.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS086736

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel